Linzagolix FDA Approval Status
FDA Approved: No
Generic name: linzagolix
Company: ObsEva SA
Treatment for: Uterine Fibroids, Endometriosis
Linzagolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the treatment of women with heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis.
Development Timeline for linzagolix
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.